Six‐Membered N ‐Heterocycle Antidiabetic Agents: Structure–Activity Relationships and Molecular Insights

Over the past several decades, extensive research has led to the development of inhibitors targeting α‐glucosidase, α‐amylase, and peroxisome proliferator–activated receptors (PPARγ) for the management of diabetes. However, the currently available antidiabetic drugs suffer from the limitations of toxicity and resistance, highlighting the need for safer and effective therapeutic agents. Six‐membered nitrogen‐containing heterocycles, their structural versatility and pharmacophoric features, exhibit diverse biological activities. The nitrogen atoms present in heterocyclic rings enhance the hydrogen‐bond interactions with key diabetes‐associated targets, thereby improving receptor binding and pharmacological performance. Recently published studies have increasingly focused on molecular hybridization strategies that incorporate nitrogen‐containing heterocycles into the core structures to yield new hybrid molecules that enhance insulin sensitivity while optimizing their efficacy and safety profiles. This review summarizes recent advances in synthetic methodologies, molecular modelling, and structure–activity relationship (SAR) analyses of nitrogen‐containing six‐membered heterocycles over the past 5 years (2020–25) targeting diabetes. The heterocyclic scaffolds discussed include the core six‐membered N ‐heterocycles such as triazine, pyridine, pyrimidine, piperidine, piperazine, and morpholine, along with their structurally diverse derivatives. Moreover, insights gained from these investigations provide a rational framework for the design and development of next‐generation antidiabetic agents with enhanced selectivity, reduced toxicity, and improved pharmacological profiles.